TEVA'S PROSTATE CANCER DRUG GETS FDA APPROVAL

Israeli drugmaker Teva's Mitoxantrone hydrochloride injection, the company's generic treatment for prostate cancer, has been approved by the U.S. FDA, the company reported.

The drug is used in combination with corticosteroids as initial treatment for patients in pain from advanced hormone-refractory prostate cancer. It can also be used in combination with other products for the initial therapy for acute nonlymphocytic leukemia in adults.

Mitoxantrone is the equivalent of the Novantrone injection, made by Swiss company Serono.